Microbot Medical Secures Patents in Multiple Global Jurisdictions
November 17 2020 - 7:00AM
Microbot Medical Inc. (Nasdaq: MBOT) announced that it has received
patents in multiple jurisdictions, further demonstrating the
Company’s continued execution of expanding and protecting its
Intellectual Property (IP) portfolio. The Company now has 40
issued/allowed patents and 23 patent applications pending
worldwide.
“As we continue to make progress on the
development, clinical and regulatory fronts, it is encouraging that
we are also achieving our goals to broaden the protection of our
novel technologies,” commented Harel Gadot, CEO, President and
Chairman. “Strengthening our IP portfolio is a critical component
of Microbot’s strategy for facilitating product evolution and
maximizing future commercial opportunities.”
The U.S. Patent and Trademark Office (USPTO)
issued a Notice of Allowance 684 pertaining to the Company’s
Self-Cleaning Shunt (SCS) device. The allowed patent application is
a Continuation of a patent, issued on July 19, 2016, and covers a
device for mitigating occlusion in an implantable catheter. The
claims are directed to a device comprising a tube having at least
one drainage opening disposed in its wall and configured for
implantation within a body cavity, further comprising a cleaning
element having at least one cleaning protrusion extending into the
opening and configured to move within the opening.
Additionally, the European Patent Office (EPO)
granted an EP Patent covering the Company’s guidewire technology
for use with endo-luminal interventions, and related to the
Company’s LIBERTYTM development. This is the second European patent
granted for this unique technology and extends protection to
include the device’s current development, having a double guidewire
comprising a first hollow guidewire and a second guidewire deployed
within the first guidewire, and an adjuster mechanism operable to
displace the second guidewire longitudinally relative to the first
guidewire between at least three states.
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a
pre-clinical medical device company that specializes in
transformational micro-robotic technologies, focused primarily on
both natural and artificial lumens within the human body.
Microbot’s current proprietary technological platforms provide the
foundation for the development of a Multi Generation Pipeline
Portfolio (MGPP).
Microbot Medical was founded in 2010 by Harel
Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of
improving clinical outcomes for patients and increasing
accessibility through the use of micro-robotic technologies.
Further information about Microbot Medical is available at
http://www.microbotmedical.com.
Safe Harbor
Statements pertaining to the registered direct
offering, timing, the amount and anticipated use of proceeds and
statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development, and
potential opportunities for Microbot Medical Inc. and its
subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management, constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 and
the Federal securities laws. Any statements that are not historical
fact (including, but not limited to statements that contain words
such as “will,” “believes,” “plans,” “anticipates,” “expects” and
“estimates”) should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, market conditions and
the satisfaction of customary closing conditions, risks inherent in
the development and/or commercialization of potential products,
including LIBERTYTM, the outcome of its studies to evaluate the SCS
and other existing and future technologies, uncertainty in the
results of pre-clinical and clinical trials or regulatory pathways
and regulatory approvals, uncertainty resulting from the COVID-19
pandemic, need and ability to obtain future capital, and
maintenance of intellectual property rights. Additional information
on risks facing Microbot Medical can be found under the heading
“Risk Factors” in Microbot Medical’s periodic reports filed with
the Securities and Exchange Commission (SEC), which are available
on the SEC’s web site at www.sec.gov. Microbot Medical disclaims
any intent or obligation to update these forward-looking
statements, except as required by law.
Investor Contact:
Michael PolyviouEVC Groupmpolyviou@evcgroup.com732-933-2754
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Apr 2023 to Apr 2024